Compile Data Set for Download or QSAR
Report error Found 233 Enz. Inhib. hit(s) with all data for entry = 10032
TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509719(US20200361871A1, Example 35.24 | US11364246, Examp...)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509689(US20200361871A1, Example 31.2 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509773(US20200361871A1, Example 92.2)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509778(US20200361871A1, Example 93.5 | US11364246, Exampl...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509722(US20200361871A1, Example 36 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509692(US20200361871A1, Example 31.4 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509756(US20200361871A1, Example 78 | 4-[[2-(4-Chloro-2-hy...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509758(US20200361871A1, Example 78.2 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509775(US20200361871A1, Example 93.2 | US11364246, Exampl...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509762(US20200361871A1, Example 81.3 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509763(US20200361871A1, Example 81.4 | N-(4-Fluoro-1-bicy...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509594(US20200361871A1, Example 3.14b | US11364246, Examp...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509649(US20200361871A1, Example 7.15 | US11364246, Exampl...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509730(US20200361871A1, Example 44 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509724(US20200361871A1, Example 38 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509757(US20200361871A1, Example 78.1 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509774(US20200361871A1, Example 93.1 | US11364246, Exampl...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509776(US20200361871A1, Example 93.3 | US11364246, Exampl...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509226(US20200361871A1, Example 1.6 | 4-[[2-(5-Chloro-2-h...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509725(US20200361871A1, Example 39 | N-(4-tert-Butylcyclo...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509630(US20200361871A1, Example 5.36 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509777(US20200361871A1, Example 93.4 | US11364246, Exampl...)
Affinity DataEC50:  70nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509579(US20200361871A1, Example 3.3a | US11364246, Exampl...)
Affinity DataEC50:  70nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509231(US20200361871A1, Example 1.10 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  80nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509647(US20200361871A1, Example 7.13 | US11364246, Exampl...)
Affinity DataEC50:  90nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509700(US20200361871A1, Example 34 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  90nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509769(US20200361871A1, Example 89 | N-tert-Butyl-4-[[2-(...)
Affinity DataEC50:  90nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509702(US20200361871A1, Example 35b | US20200361871A1, Ex...)
Affinity DataEC50:  100nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509640(US20200361871A1, Example 7.6 | US11364246, Example...)
Affinity DataEC50:  100nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509720(US20200361871A1, Example 35.25 | US11364246, Examp...)
Affinity DataEC50:  100nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509737(US20200361871A1, Example 48 | 4-[[2-(5-Fluoro-2-hy...)
Affinity DataEC50:  100nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509732(US20200361871A1, Example 46a | US11364246, Example...)
Affinity DataEC50:  110nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509576(US20200361871A1, Example 3 | N-tert-Butyl-4-[[2-(5...)
Affinity DataEC50:  110nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509771(US20200361871A1, Example 92 | 4-[[2-(4-Chloro-3-hy...)
Affinity DataEC50:  110nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509586(US20200361871A1, Example 3.6b | US11364246, Exampl...)
Affinity DataEC50:  120nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509688(US20200361871A1, Example 31 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  120nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509770(US20200361871A1, Example 90 | N-tert-Butyl-4-[[2-(...)
Affinity DataEC50:  120nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509723(US20200361871A1, Example 37 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  120nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509596(US20200361871A1, Example 3.17b | US11364246, Examp...)
Affinity DataEC50:  120nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509650(US20200361871A1, Example 7.16 | US11364246, Exampl...)
Affinity DataEC50:  130nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509641(US20200361871A1, Example 7.7 | US11364246, Example...)
Affinity DataEC50:  130nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509662(US20200361871A1, Example 15 | N-tert-Butyl-4-[[2-(...)
Affinity DataEC50:  130nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509679(US20200361871A1, Example 30.1 | 4-[[2-(2-Chlorophe...)
Affinity DataEC50:  140nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509625(US20200361871A1, Example 5.24 | US11364246, Exampl...)
Affinity DataEC50:  140nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509675(US20200361871A1, Example 25.1 | 4-[[2-(5-tert-Buty...)
Affinity DataEC50:  140nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509772(US20200361871A1, Example 92.1 | US11364246, Exampl...)
Affinity DataEC50:  140nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509580(US20200361871A1, Example 3.4a | US11364246, Exampl...)
Affinity DataEC50:  140nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509631(US20200361871A1, Example 5.37 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  150nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509711(US20200361871A1, Example 35.15 | US11364246, Examp...)
Affinity DataEC50:  150nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509648(US20200361871A1, Example 7.14 | US11364246, Exampl...)
Affinity DataEC50:  150nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

Displayed 1 to 50 (of 233 total ) | Next | Last >>
Jump to: